Showing 41 - 60 results of 51,264 for search '(( significant case based ) OR ( significant ((teer decrease) OR (we decrease)) ))', query time: 1.25s Refine Results
  1. 41

    Significantly Enriched Pathways. by Jiyong Zhang (2498740)

    Published 2025
    “…By comparing samples from NAFLD patients and healthy controls, we identified 1,770 significant DEGs, with 1,073 being upregulated and 697 downregulated. …”
  2. 42

    The effect of HA digestion and HA replenishment alone or with CS on barrier function measured by TEER. by Charlotte J. van Ginkel (20790466)

    Published 2025
    “…PS decreased TEER. (C) Different treatments (treatment groups n = 8)with HA and/or CS did not affect TEER recovery after PS treatment, full recovery was seen in all groups after 24 hours. …”
  3. 43

    Base-case results. by Mingxi Xie (19812594)

    Published 2024
    “…Clinical findings have showed that deprescribing service significantly decreased inappropriate PPIs utilization. …”
  4. 44
  5. 45

    The base case analysis. by Wenwang Lang (20293527)

    Published 2025
    “…</p><p>Results</p><p>In the base-case scenario, adding benmelstobart and anlotinib to chemotherapy increased QALYs by 0.34 at an additional cost of $24,684.07, yielding an ICER of $71,559.84 per QALY. …”
  6. 46
  7. 47

    Base-case results. by Shuo Kang (1306860)

    Published 2025
    “…One-way and probabilistic sensitivity analyses were conducted to estimate the robustness of the model results,</p><p>Results</p><p>In base-case analysis, compared with toripalimab plus chemotherapy and chemotherapy alone, ITH-testing directed therapy could bring additional 0.14 QALYs and 0.29 QALYs, with marginal costs of $3750.75 and $7778.18, resulting in the ICER of $27,353.27/QALY and $26,461.46/QALY, respectively, which lower than the Chinese willingness-to-pay (WTP) threshold. …”
  8. 48
  9. 49

    Base-case analysis. by Akiko Kowada (14659965)

    Published 2023
    “…The willingness-to-pay (WTP) threshold was set at US$50,000 per QALY gained. In the base-case analysis, HTLV-1 antenatal screening (US$76.85, 24.94766 QALYs, 24.94813 LYs, ICER; US$40,100 per QALY gained) was cost-effective compared with no screening (US$2.18, 24.94580 QALYs, 24.94807 LYs). …”
  10. 50
  11. 51
  12. 52
  13. 53
  14. 54
  15. 55
  16. 56
  17. 57
  18. 58
  19. 59
  20. 60